Therapeutic Response

HER2-positive status confers therapeutic sensitivity to Carboplatin in combination with Docetaxel and Trastuzumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Herceptin (trastuzumab) [product monograph]. HC. Health Canada approved trastuzumab in combination with docetaxel and carboplatin for the treatment of early stage breast cancer patients with ECOG 0-1 status, whose tumors overexpress HER2.